In an AMA (ask me anything) recently on Reddit, representatives of the the Multidisciplinary Association For Psychedelic Studies (MAPS) took some time to answer questions and clear the always-foggy air on drugs and their uses.
Thanks to some diligent work from our friends at Mixmag, we’ve learned that a good chunk of the convo was spent discussing the state of the hot-button item MDMA. Despite how controversial the little drug is, MAPS officials said that it’s being considered as a prescription in psychotherapy and the fight against post-traumatic stress disorder (PTSD), as we’ve learned in the video below, via MAPS.
Currently in “phase two” of their route to approval for prescription use, the proposed pharmaceutical weapon against these afflictions will need to complete the third and final phase in standard testing, scheduled for 2016-2020, before it can be presented to the FDA (Federal Drug Agency) and European equivalent, the EMA (European Medicines Agency), for approval. According to the AMA, phase three will include deciding on a good manufacturing process (GMP) manufacturer and a post-phase two meeting in 2016, which is where they will finalize their phase three strategy and learn if they’ve been approved for any accelerated development on the project.
If all goes well, we could be looking at MDMA as a tool in the fight against psychological disorders as soon as 2021. Check back soon for updates.